
An Antiviral to Treat Progressive Multifocal Leukoencephalopathy_(Pml)Award last edited on: 8/6/15
Sponsored Program
SBIRAwarding Agency
NIH : NIAIDTotal Award Amount
$224,999Award Phase
1Solicitation Topic Code
-----Principal Investigator
Emre KoyuncuCompany Information
Evrys Bio LLC (AKA: Forge Life Sciences LLC)
3805 Old Easton Road
Doylestown, PA 18902
Doylestown, PA 18902
(267) 893-6755 |
business@evrysbio.com |
www.forgelifescience.com |
Location: Single
Congr. District: 01
County: Bucks
Congr. District: 01
County: Bucks
Phase I
Contract Number: 1R43AI118232-01Start Date: 2/5/15 Completed: 1/31/16
Phase I year
2015Phase I Amount
$224,999Public Health Relevance Statement:
Public Health Relevance:
Progressive multifocal leukoencephalopathy (PML) is a devastating disease without a cure. It is caused by a virus infection that results in brain dysfunction and often death. Immunosuppressed patients are at risk for PML including AIDS patients and those taking effective medications to treat autoimmune diseases such as multiple sclerosis and rheumatoid arthritis. FORGE Life Science is developing a drug to treat PML that would save lives and additionally improve the well-being of the large population of patients benefitting from antiretroviral and autoimmune therapies by alleviating the risk of fatality caused by PML.
Project Terms:
Acquired Immunodeficiency Syndrome; adalimumab; Address; Adult; Agonist; Animal Model; Anti-inflammatory; Anti-Inflammatory Agents; Anti-Retroviral Agents; Antimalarials; Antiviral Agents; Area; Astrocytes; Autoimmune Diseases; Autoimmune Process; base; Biochemical; Biodistribution; Biological Assay; Biological Markers; Biological Sciences; Blood - brain barrier anatomy; Brain; Brain Injuries; Cell Culture Techniques; cell type; Cells; Central Nervous System Infections; Cessation of life; Cidofovir; Clinic; Clinical; clinically relevant; Crohn's disease; Cytarabine; cytotoxicity; Demyelinations; Development; Disabled Persons; Disease; Disease Progression; DNA-Directed DNA Polymerase; drug candidate; Drug Kinetics; Drug Targeting; effective therapy; Enzymes; Etanercept; Excision; Exhibits; Functional disorder; gene function; Genes; Genetic Transcription; Goals; Growth; Highly Active Antiretroviral Therapy; Human; Immune; immune function; Immune system; Immunocompromised Host; immunosuppressed; Immunosuppressive Agents; improved; In Vitro; in vitro testing; in vivo; indexing; Individual; Infection; Inflammation; Inflammatory; Inflammatory Response; infliximab; Inhibitory Concentration 50; innovative technologies; JC Virus; Latent Virus; Lead; lead series; Literature; lytic replication; Measures; meetings; Mefloquine; Metabolic; Microdialysis; Modification; Multiple Sclerosis; natalizumab; Natural immunosuppression; Neuraxis; Neurons; novel; novel strategies; nucleoside analog; Oligodendroglia; Outcome; patient population; Patients; Pattern; Penetrance; Penetration; Personal Satisfaction; Pharmaceutical Preparations; Pharmacodynamics; Phase; Play; pre-clinical; preclinical efficacy; preclinical safety; Prevalence; Progressive Multifocal Leukoencephalopathy; Promotor (Genetics); Property; Proteins; Psoriasis; public health relevance; Rare Diseases; receptor; reconstitution; Recovery; restoration; Rheumatoid Arthritis; Risk; Role; scaffold; Series; single molecule; Sirtuins; Small Business Innovation Research Grant; small molecule; Staging; Structure; Survivors; Symptoms; Syndrome; Testing; Therapeutic; Therapeutic immunosuppression; transcription factor; Translations; Validation; Viral; viral DNA; Virus; Virus Diseases
Phase II
Contract Number: ----------Start Date: 00/00/00 Completed: 00/00/00